- Home
- Companies
- usa massachusetts
- immune response
Show results for
Refine by
Immune Response Suppliers In Usa Massachusetts
21 companies found
based inCambridge, MASSACHUSETTS (USA)
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP ...
Indication: PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and ...
based inDreieich, GERMANY
Biotest - innovation in haematology, clinical immunology and intensive care medicine. Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and ...
based inHopkinton, MASSACHUSETTS (USA)
Isto Biologics is an orthobiologics company dedicated to improving patient quality of life by using the science of human biology to advance solutions for spine, orthopedics, and sports medicine. Our novel solutions for cell therapy and rapid bone ...
InQu® is the cell-friendly biosynthetic™ bone graft with proven clinical efficacy leading to faster bone ...
based inFramingham, MASSACHUSETTS (USA)
Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology. We collaborate with a global community of researchers to develop and translate new technologies ...
COVI-QUANT™ is an ELISA test available through Kephera’s CLIA laboratory. Studies show that not all individuals develop a strong immune response after COVID-19 infection or vaccination, especially those ...
based inWoburn, MASSACHUSETTS (USA)
Aegle Therapeutics is a first in class, phase 1/2a stage biotechnology company isolating extracellular vesicles including exosomes (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa ...
Advancement of extracellular vesicle therapy to the patient has been hampered by an inability to isolate extracellular vesicles in useful quantities while preserving their structural and functional integrity. EVs derived from MSCs enjoy the same ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients ...
based inCambridge, MASSACHUSETTS (USA)
The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against ...
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone ...
based inIllkirch-Graffenstaden, FRANCE
Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for ...
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
The inauguration of monoclonal antibodies (mAbs), derived from mice, were immunogenic in humans. These molecules were first synthesized in 1975 by Georges Köhler and César Milstein through the use of hybridoma technology. Later, in 1984, another ...
based inCambridge, MASSACHUSETTS (USA)
At BlueRock, our mission is to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition. Until recently, scientists believed that mature adult cells were permanently locked into their ...
based inWoburn, MASSACHUSETTS (USA)
We are leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms and enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and ...
In order to increase the therapeutic efficiency of such vaccines, adjuvants are used with vaccines to augment the immune response. There are several types of adjuvants with different modes of action. Adjuvants form ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel immunomodulatory STING ...
based inBoston, MASSACHUSETTS (USA)
Like our customers and their consumers, we needed a real change in the probiotic world that would result in products with benefits we can all feel. We knew current probiotics on the market deliver unpredictable benefits for some people, while not ...
based inWaltham, MASSACHUSETTS (USA)
Exosome Diagnostics, Inc. is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. Exosomes are lipid bilayer covered microvesicles shed by solid ...
based inGaithersburg, MASSACHUSETTS (USA)
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly ...
Building upon the proven success of SEL-212, ImmTOR has exciting potential to give rise to antigen-specific immunity across a range of immunogenic compounds when co-administered with biologic therapies like ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
DSP-0509 is an investigational Toll-like receptor (TLR) 7 agonist, which is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain immune-mediated antitumor ...
based inCambridge, MASSACHUSETTS (USA)
AOBiome has identified significant therapeutic opportunities caused by the adverse impact of the modern environment on human physiology. The human body relies on a system of multiple microorganisms, chemistries, and pathways which have shaped the ...
based inBoston, MASSACHUSETTS (USA)
Day Zero Diagnostics is located in the heart of the thriving Boston Landing area. This cutting-edge innovation space brings together the area’s leading science and technology companies and provides us with access to state-of-the-art research ...
Antibiotic resistance is an escalating global crisis, where the spread of drug resistance is outpacing the development of new ...
based inCambridge, MASSACHUSETTS (USA)
Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will be fundamental to help the world in rethinking what's ...
Vaxxas has developed novel technologies that enable vaccines to be applied to the tips of the microprojections under sterile conditions. The HD-MAP delivers the vaccine on its microprojections efficiently to the high density populations of ...
